Update on erythropoietin treatment: Should hemoglobin be normalized in patients with chronic kidney disease?

Journal of the American Society of Nephrology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Paoletti, Ernesto ^a   Cannella, Giuseppe ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; EXERCISE; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HEMODIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MORTALITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

EID: 33645470185     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005121325     Document Type: Conference Paper

References (27)

1. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 11: 335-342, 2000
2. McMahon LP, Johns JA, McKenzie A, Austin M, Fowler R: Haemodynamic changes and physical performance at comparative levels of haemoglobin after long/term treat-ment with recombinant erythropoietin. Nephrol Dial Transplant 7: 1199-1206, 1992
3. Xia H, Ebben J, Ma JZ, Collins AJ: Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10: 1309-1316, 1999
4. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619, 1999
5. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465-2473, 2001
6. Cannella G, LaCanna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Mombelloni S, Visioli O, Maiorca R: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 6: 31-37, 1991
7. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 37[Suppl 1]: S1-S238, 2001
8. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougall IC, Macleod A, Wiecek A, Cameron S: Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19[Suppl 2]: 6-15, 2004
9. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15: 1425-1430, 2000
10. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58: 1325-1335, 2000
11. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG: A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18: 353-361, 2003
12. McMahon LP, McKenna MJ, Sangkabutra T, Mason K, Sostaric S, Skinner SL, Burge C, Murphy B, Crankshaw D: Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant 14: 1182-1187, 1999
13. Painter P, Moore G, Carlson L, Paul S, Myll J, Phillips W, Haskell W: Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life. Am J Kidney Dis 39: 257-265, 2002
14. Ofsthun N, LaBrecque J, Lacson E, Keen M, Lazarus JM: The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63: 1908-1914, 2003
15. Strippoli GFM, Craig JC, Manno C, Schena FP: Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled trials. J Am Soc Nephrol 15: 3154-3165, 2004
16. Besarab A, Bolton K, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
17. Paoletti E, Cassottana P, Bellino D, Specchia C, Messa P, Cannella G: Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis 40: 728-736, 2002
18. Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP: PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 18: 89-100, 2003
19. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A: Effect of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 15: 148-156, 2004
20. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Schwartz I, Steinbruch S, Iaina A: The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18: 141-146, 2003
21. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77: 176-185, 1997
22. Gouva C, Nikolopoulos P, Ioannidis JPA, Siamopoulos KC: Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int 66: 753-760, 2004
23. Rossert J, Fouqueray B, Bolla JJ: Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 14[Suppl 2]: S173-S177, 2003
24. Lacson E, Ofshtun N, Lazarus JM: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 41: 111-124, 2003
25. Cotter DJ, Stefanik K, Zhang Y, Thamer M: Improved survival with higher hematocrits: Where is the evidence? Semin Dial 17: 181-183, 2004
26. Tonelli M, Winkelmayer WC, Jindal ICK, Owen WF, Manns BJ: The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 64: 295-304, 2003
27. Ritz E, Schwenger V: The optimal target hemoglobin. Semin Nephrol 20: 382-386, 2000